What Does the Market Think of agilon health inc. (AGL) Shares?

This morning we watched agilon health inc. drop -13.4% to a price of $23.21 per share. The large-cap Medical Distribution company is now trading -20.49% below its average target price of $29.19. Analysts have set target prices ranging from $22.0 to $41.0 per share for agilon health inc., and have given the stock an average rating of buy.

agilon health inc. has an elevated short interest of 22.9%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 15.63. Only 1.11% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 106.1% of agilon health inc. shares are held by institutional investors, which indicates a high level of confidence in the stock.

Institutions Invested in agilon health inc.

Date Reported Holder Percentage Shares Value
2022-12-31 Clayton, Dubilier & Rice, LLC 47% 194,611,308 $4,516,928,280
2022-12-31 FMR, LLC 11% 46,671,306 $1,083,240,969
2022-12-31 Morgan Stanley 9% 38,439,976 $892,191,807
2022-12-31 Capital World Investors 9% 37,918,473 $880,087,723
2022-12-31 Wellington Management Group, LLP 6% 22,745,297 $527,918,322
2022-12-31 Vanguard Group, Inc. (The) 5% 19,247,393 $446,731,973
2022-12-31 Capital Research Global Investors 3% 13,428,559 $311,676,842
2022-12-31 Durable Capital Partners LP 2% 8,842,728 $205,239,708
2022-12-31 Blackrock Inc. 2% 8,686,090 $201,604,140
2022-12-31 Rock Springs Capital Management, LP 2% 7,872,500 $182,720,717
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.